Trv Gp Iv LLC Has $129.82 Million Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)

Trv Gp Iv LLC lessened its holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) by 12.2% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 16,859,075 shares of the company’s stock after selling 2,342,400 shares during the quarter. Tango Therapeutics makes up 80.1% of Trv Gp Iv LLC’s holdings, making the stock its largest holding. Trv Gp Iv LLC owned about 15.74% of Tango Therapeutics worth $129,815,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. grew its stake in Tango Therapeutics by 32.6% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,964 shares of the company’s stock worth $230,000 after acquiring an additional 7,128 shares in the last quarter. SG Americas Securities LLC increased its holdings in Tango Therapeutics by 16.0% during the 1st quarter. SG Americas Securities LLC now owns 30,429 shares of the company’s stock worth $242,000 after purchasing an additional 4,203 shares during the period. Vanguard Group Inc. raised its position in Tango Therapeutics by 3.4% during the 1st quarter. Vanguard Group Inc. now owns 3,080,885 shares of the company’s stock valued at $24,462,000 after purchasing an additional 101,673 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Tango Therapeutics by 12.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,771 shares of the company’s stock worth $102,000 after buying an additional 1,426 shares during the period. Finally, Paloma Partners Management Co purchased a new stake in shares of Tango Therapeutics in the 1st quarter worth $80,000. Institutional investors own 78.99% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on TNGX shares. B. Riley decreased their price objective on Tango Therapeutics from $16.00 to $8.00 and set a “buy” rating for the company in a report on Monday, November 11th. HC Wainwright restated a “buy” rating and issued a $13.00 price target on shares of Tango Therapeutics in a report on Friday, November 8th. Wedbush increased their price objective on shares of Tango Therapeutics from $11.00 to $13.00 and gave the company an “outperform” rating in a research note on Thursday, August 8th. Finally, Guggenheim lowered their target price on Tango Therapeutics from $18.00 to $8.00 and set a “buy” rating for the company in a report on Thursday, November 7th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, Tango Therapeutics presently has an average rating of “Buy” and an average target price of $13.14.

Insider Transactions at Tango Therapeutics

In other news, insider Boxer Capital Management, Llc sold 633,000 shares of the business’s stock in a transaction on Friday, October 25th. The shares were sold at an average price of $6.87, for a total transaction of $4,348,710.00. Following the sale, the insider now directly owns 6,690,642 shares of the company’s stock, valued at $45,964,710.54. The trade was a 8.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Rock Ventures Iv L.P. Third sold 150,000 shares of the business’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $10.09, for a total value of $1,513,500.00. Following the sale, the insider now owns 17,201,475 shares in the company, valued at approximately $173,562,882.75. The trade was a 0.86 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 4,830,400 shares of company stock valued at $23,835,132. Corporate insiders own 6.30% of the company’s stock.

Tango Therapeutics Stock Down 1.8 %

NASDAQ:TNGX opened at $3.85 on Friday. The stock has a market capitalization of $413.56 million, a price-to-earnings ratio of -3.26 and a beta of 0.88. Tango Therapeutics, Inc. has a 52 week low of $2.70 and a 52 week high of $13.01. The firm has a 50 day moving average of $6.65 and a 200 day moving average of $8.14.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.